

Seegene rolls out COVID-19 mutant identification test

Feb. 9, 2021-[Seegene](#) announced it has developed the first COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.

The Allplex SARS-CoV-2 Variants I assay can identify major genetic variations that seem to have originated from the U.K. and South Africa, as well as other regions including Japan and Brazil; it can also prescreen a potential new variant. The assay uses the company's multiplex real-time PCR method of mTOCE, which allows the test to detect a target-specific spot where mutation occurs, enabling detection and differentiation of the coronavirus as well as its mutated versions with a single tube of reagent. Seegene's technology also includes an endogenous internal control that can verify the testing process, including proper sample collection.

The company plans to supply its COVID-19 variant tests to organizations and governments worldwide.